A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), ...

Incyte said on Monday its experimental combo therapy helped patients live longer without their disease worsening in a late-stage study of a type of blood cancer, sending its shares up about 3% in ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Diffuse lymphomas of B-cell origin represent a heterogeneous group of lymphoid neoplasms. The histologically aggressive subtypes of diffuse B-cell lymphomas include biologically different entities, ...

Diffuse large B-cell lymphoma (DLBCL) account for approximately 40% of adult non-Hodgkin lymphomas. It is clinically, morphologically and genetically a heterogeneous group of tumors composed of large ...

Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue. There’s a need for access to treatment and a need for better drugs in diffuse large B-cell lymphoma ...

Researchers identified genomic alterations that defined four subtypes of diffuse large B-cell lymphoma that may predict which patients will respond to treatment and have longer OS, according to study ...

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...